HTS and Proteomics

核心D对于加州大学洛杉矶分校-CMCR的核心原则至关重要，即辐射减少量的类别 损害可以通过它们的化学结构和/或它们所利用的生物途径来确定。核心D 已经并将继续提供项目工作背后的技术推动力 小分子文库的高通量筛选(HTS)，目的是发现新的缓解剂 辐射损伤。Core D将HTS集中在一个最先进的设施中，该设施已经证明了其价值 UCLA-CMCR，鉴定了几个先导化合物家族。此外，为了处理这些数据 并以可以挖掘其结构活性的形式将其提供给CMCR 关系和其他相关化学和生物信息核心D，通过试点研究 资金，已与协作药物发现(CDD)建立关系，以利用其行业优势 数据库用于这些目的。其他CMCR也可以访问这些数据。现在，他们的家庭 先导化合物已经确定，未来还会有更多。核心D已进一步扩展到包括 荣格博士领导下的药物化学家，他将在设计和合成类似物方面发挥核心作用 活性化合物，以确定对活性负责的化学结构，提高其类药物性质， 以及它们的功效。这种关系也是通过试点研究资助启动的。最后，核心D 主要以质谱学的形式提供蛋白质组学，以寻找生物的分子特征 有效缓释剂利用的途径，以探索这些化合物的作用机理。

Core D is critical for the central tenet ofthe UCLA-CMCR, which is that classes of mitigators of radiation damage can be identified by their chemical structures and/or the biological pathways that they utilize. Core D has provided and will continue to provide the technological driving force behind the work ofthe projects in high-throughput screening (HTS) of small molecule libraries with the aim of discovering novel mitigators of radiation damage. Core D centralizes HTS in a state-of-the-art facility that has already proven its value to the UCLA-CMCR, with several families of lead compounds identified. Additionally, in order to deal with the data that has been generated and to provide it to the CMCR in a form in which it can be mined for structureactivity relationships and other relevant chemical and biological information Core D, through pilot research funding, has established a relationship with Collaborative Drug Discovery (CDD) to use its an industrialstrength database for these purposes. Access to this data is available to other CMCRs. Now that families of lead compounds have been identified, with more to come. Core D has been further expanded to include pharmaceutical chemists under Dr. Jung, who will play a central role in design and synthesis of analogues of active compounds to identify chemical structures responsible for activity, to improve their drug-like qualities, and their efficacy. This relationship also was initiated through pilot research funding. Finally, Core D provides proteomics primarily in the form of mass spectrometry to seek molecular signatures ofthe biological pathways utilized by effective mitigators so as to probe mechanism of action of these compounds.